The Advocacy Training Session

 

The first training for certification will include a
variety of topics to give advocates a well-grounded understanding of
methadone treatment, research, regulations and laws that protect
methadone patients and programs.

 

  1. Addiction
    and Methadone
    Tom Payte, MD (Drug Dependence
    Associates) and Joycelyn Woods, MA. (NAMA) The
    biological constructs of addiction will be explained in a way that
    can be understood by lay people (i.e. opiate receptors, Endorphins)
    Methadone dose and what is considered an adequate dose and why it is
    important and what methadone does to make you feel normal.
  2. Regulations
    and Accreditatio
    n
    C. Todd
    Rosendale (CSAT/DPT), Sharon Dow (Joint Commission), Bettye Harrison
    (CARF) and Joanne Page (COA).The new federal regulations will be explained:  What
    they are and how they relate to the state regulations? Accreditation
    and what an accreditation survey is, how it is done, and how
    advocates can be involved.
  3. The
    Different Faces of Advocacy

    Presenters to be announced.
    Advocates from around the country will explain what they do to
    advance the goals of methadone advocacy. This session will also
    explain the different types of advocacy that advocates are involved
    in.
  4. How
    to End Methadone Stigma
    Herman Joseph, Ph.D. The history of
    methadone stigma will be presented and how it has impacted methadone
    treatment and the recipients of it. A plan for advocates to work on
    for ending it will be revealed.
  5. Advocate
    Certification

    Walter Ginter (NAMA Training and Certification Director) What is certification and how it
    will professionalize those committed to methadone advocacy.  The Advocates Code of Ethics, the Goals of Methadone
    Advocacy, and Advocate Certification.

         Top

Similar Posts

  • The Discovery of Endorphins

    Admin 02/02/2023

    For years it had been suspected that opiates had specificbinding sites in the brain. There were several attempts tolocate these sites, but the existing technologies were unable todistinguish between the non specific binding to tissue and thespecific binding to receptors. It must be mentioned here thatthe first attempt to actually measure specific opiate bindingwas in…

  • Methadone Advocacy

    Admin 04/11/2021

      The National Alliance of Methadone Advocates (nama) holds the view that every individual who believes in methadone treatment is at least a potential Certified Methadone Advocate (CMA). We encourage all supporters of methadone treatment, patient and non-patient, to become Certified Methadone Advocates so that all energies directed toward the advancement of methadone treatment produce…

  • Presidential Notes

    Admin 03/17/2022

    Stan Novick Stigma (STIG-ma): noun {From the Latin for “mark” or “brand”} a scar left by a hot iron a mark of shame or discredit an identifying mark or characteristic, i.e.: a specific diagnostic sign of a disease Everyone touched positively by methadone maintenance treatment is familiar with stigmatization. Patients, family members, friends, staff- we…

  • Doctors Still Waiting to Test Buprenorphine’s Promise

    Admin 05/08/2022

    Join Together Online January 21, 2003 While 616 physicians nationwide are now authorized to prescribe buprenorphine, its widespread use is still an issue, the Baltimore Sun reported on January 15. Product availability is the first problem. Despite receiving FDA approval in October, the manufacturer did not ship the product to pharmaceutical warehouses until last week….

  • FOR IMMEDIATE RELEASE

    Admin 01/30/2022

    October 9, 2002 NIDA Contact: Michelle Person 301-443-6245 SAMHSA Contact: Leah Young 301-443-8956 NIDA Research and SAMHSA Physician Training Combine to Put Care for Opiate Dependence in Hands of Family Doctor. Buprenorphine, a new medication developed through more than a decade of research supported by the National Institute on Drug Abuse (NIDA), will now become…